Expected Currency Impact

January 31, 2024
This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding our environmental, social and governance framework; or regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from such products; or regarding research and development activities and timelines; or regarding current and potential future or pending collaborations and alliances; or by discussions of strategy, plans, expectations or intentions, including with respect to current, planned and potential future actions in the areas of our access principles; or regarding innovation for global health to drive impact in neglected tropical diseases; or regarding our focus on innovation and equitable access to medicines; or regarding our commitment to global health R&D; or regarding our environmental commitments on net-zero, circular economy, plastic neutrality and water sustainability. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: disruptions of our manufacturing or supply chain impacting our ability to meet demand for our products in the future; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this presentation; the potential that the strategic benefits, synergies or opportunities expected from the transactions described, may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and is expected to continue this year; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, including, among others, product liability litigation, disputes and litigation with business partners or business collaborators and intellectual property disputes; our performance on environmental, social and governance measures and our ability to achieve our environmental, social and governance goals and targets; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
Expected currency impact for Q1 and full year 2024

Currency impact vs. PY
%pts, assuming late-January exchange rates prevail in 2024

FX impact on Net sales

<table>
<thead>
<tr>
<th></th>
<th>Q4 FY</th>
<th>Q1 FY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>-2</td>
<td>-2</td>
</tr>
<tr>
<td>2024</td>
<td>-2</td>
<td>-1</td>
</tr>
</tbody>
</table>

FX impact on Core operating income

<table>
<thead>
<tr>
<th></th>
<th>Q4 FY</th>
<th>Q1 FY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>-8</td>
<td>-5 to</td>
</tr>
<tr>
<td>2024</td>
<td>-7</td>
<td>-6</td>
</tr>
</tbody>
</table>

Q4 Core OpInc FX impact includes approximately -2%pts from the effect of mid Dec Argentina ARS devaluation

1. IFRS requires for our Argentina subsidiary, as it operates in a hyperinflation economy, to translate for consolidation purposes their full year income statement to our USD presentation currency using the ARS closing rate, and not using the average exchange rate for the period. This results in the 9-months and the Q4 devaluation impact being recognized in Q4.
Backup

Fx impact as presented in early January
Expected currency impact for Q1 and full year 2024

Currency impact vs. PY
%pts, assuming early-January exchange rates prevail in 2024

FX impact on Net sales
-2  -2  -1 to -2  0 to -1
Q4  FY  Q1  FY
2023  2024

FX impact on Core operating income
-8  -7  -6  -3
Q4  FY  Q1  FY
2023  2024

Q4 Core OpInc FX impact includes approximately -2%pts from the effect of mid Dec Argentina ARS devaluation

1. IFRS requires for our Argentina subsidiary, as it operates in a hyperinflation economy, to translate for consolidation purposes their full year income statement to our USD presentation currency using the ARS closing rate, and not using the average exchange rate for the period. This results in the 9-months and the Q4 devaluation impact being recognized in Q4.